Clinical trial to aid evaluation of patients with suspected parkinsonian syndromes GE Healthcare announces clinical trial and study to aid evaluation of patients with suspected parkinsonian syndromes

 
View Press Release
 
"Having a PET option for dopamine transporter imaging in patients with parkinsonian syndromes could be highly relevant for an early differential diagnosis."
–Professor Olivier Rascol
 Clinical Pharmacology
 Toulouse University Hospital
 
 
"This new SPECT agent may offer a faster imaging workflow which could provide more convenience for patients with suspected parkinsonian syndromes and greater efficiency for the imaging clinic. It also holds promise in potentially making dopamine transporter imaging more accessible if approved."
 
 
–Dr. John Seibyl
  Board Chairman and Distinguished Scientist
  Institute for Neurodegenerative Disorders, New Haven, Connecticut
 
View Press
Release
CONTRAINDICATIONS
ADVERSE REACTIONS
GE, 2022
GE and the GE Monogram are trademarks of GE.
March 2022  JB06680US
 
 
•  Do not reply to this email as it was sent from an unmonitored account.
 
•  Unsubscribe from the Breaking News.
 
•  Reset your password.
 
•  Contact AuntMinnie.com support.
 
•  AuntMinnie.com Privacy Policy.
 
•  Email sent to: .

AuntMinnie.com, 671 N Glebe Road, Suite #1610, Arlington, VA 22203 USA
+1 520-298-1000